SHANGHAI, NANJING, China and PLEASANTON, Calif., Sept. 18, 2025 /PRNewswire/ — IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announced that the 36-month […]
SHANGHAI, NANJING, China and PLEASANTON, Calif., Sept. 18, 2025 /PRNewswire/ — IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announced that the 36-month […]
—— The Phase 1b/2 study FUMANBA-1 demonstrates Equecabtagene Autoleucel led to deep and durable responses in patients with R/RMM —— The data shows the overall response rate（ORR）was 96.1%，the ORR reached 98.9% among the patients without […]
SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 30, 2024 /PRNewswire/ — On September 23, in Rio de Janeiro, on the eve of the International Myeloma Society (IMS) Annual Meeting, Dr. Yongke Zhang, Chief Scientific […]
